大湾区慢性创面医护康标准化体系建设联盟,《中国科技论文》体表外科卷编辑委员会,黄广涛1,吴 军1,郇京宁1,2
(1.深圳大学第一附属医院(深圳市第二人民医院)烧伤整形科,广东深圳518000;2.上海交通大学医学院附属瑞金医院烧伤整形与创面修复科,上海200011)
摘要:负压封闭引流技术(negative pressure wound therapy, NPWT)自2017年国内首部烧伤外科应用专家共识发布以来,其技术类型与临床应用范围均取得了显著拓展。特别是在促进各类急慢性创面愈合及预防外科手术部位感染方面,已累积了大量高质量循证证据。为整合国内外最新研究成果与临床实践经验,规范操作标准,提升治疗水平,国内创面修复相关多学科领域的专家共同撰写了本更新版共识。本共识汇聚了国内多位在创面相关的多学科领域的专家,结合国内外最新研究成果,遵循严谨的循证医学原则,采用系统综述方法,聚焦于NPWT的技术分类、适应症、参数优化及并发症处理等核心议题。工作小组系统检索了PubMed、Web of Science、IEEE Xplore及中国知网等数据库中2015—2025年相关文献,共获得791篇。经去重、筛选,并根据纳入标准(临床研究、随机对照试验、meta分析及相关共识等)最终纳入210篇文献进行证据综合与评价。本共识旨在为创面修复相关学科的临床医生提供基于最新证据、统一且可操作的治疗方案与技术规范。共识内容充分结合了我国临床实践的现状与需求,以期推动NPWT在国内的合理、规范及高效应用,最终惠及广大患者。
关键词:负压封闭引流技术;手术部位感染;创面修复;手术切口并发症
Yesica Y. Quiroz 1 , Enver Moncada 2 , Erika Llorens 3 , Ivan Schwartzmann 4 , Jorge Caffarati 5 , Anna Bujons *
Summary
Introduction
Paratesticular sarcoma is an aggressive malignant tumor of mesenchymal origin. The rhabdo-myosarcoma is the most common among children. Rhabdomyosarcoma treatment consists of surgery, chemotherapy and radiotherapy. Prognosic depends on local recurrence and distant metastasis.
Material and methods
We present the case of a 16-year-old male, who in April 2016 underwent right radical orchiectomy surgery by testicular mass rapidly evolving, with pathological results indicating a paratesticular rhabdomyosarcoma. The extension study showed a precaval adenopathy suggestive of lymph node metastasis, therefore it was a high-grade rhabdomyosarcoma. There was an appropriate response after chemotherapy (Protocol EpSSG RMS2005) and we decided to perform a robotic.
Results
We performed a transperitoneal approach with 8 mm trocar and 12 mm optica trocar. We accessed the retroperitoneal space through a latero-colic incision. Then we performed a craniocaudal lymph node dissection until the aortic bifurcation. The surgical time was 240 min with a blood loss of 200 ml. There were no complications. The patient was discharged on the fourth day after surgery. Pathology showed metastasis of rhabdomyosarcoma without capsular rupture. After two months, we placed the left testicle into inguinal canal prior to radiotherapy.
Conclusions
Robotic lymph node metastasis lymphadenectomy from paratesticular sarcomas is a feasible treatment with the advantage of minimally invasive surgery and acceptable morbidity.
Authors
Christopher Edens
Patricia Stevenson
Keywords
Biofilm
Evidence-Based Practice
Issue: Volume 65 - Issue 1 - January 2019 ISSN 2640-5245
Index: Wound Management & Prevention 2019;65(1):8-9.
Login or Register to download PDF
A study from Queensland University of Technology in Australia (Brisbane, Australia) and the University of Southern California (Los Angeles, CA) revealed diabetes-related lower extremity complications are now among the top 10 leading causes of health disability in the world, ahead of chronic kidney disease, ischemic heart disease, and cardiovascular disease.1-4 Further analysis of the diabetic cohort predicted this population will produce as many as 148 million foot ulcers in their lifetime, making diabetic lower-extremity complications the leading cause of infection, hospitalization, and amputation worldwide.1 The most astounding revelation from the study is not the fact that diabetic limb complications have attained such a predominant position in global health issues, but rather that the leading cause was infection and a perceived persistent failure to follow evidence-based medicine (EBM).3 Studies2-4 have proven repeatedly that the use of EBM often is the determining factor between a healed and nonhealed wound and is strongly related to outcomes; however, the prevalence of EBM practice has not diminished the persistent threat of infection.
Although what constitutes best evidence for treating wounds continues to be debated, infection remains the elephant in the room. Whether the controversy surrounds high bioburden or critical colonization or infection, the outcome is the same — a nonhealing wound.
According to a 2014 study,5 >99% of all wound bacteria exist within a biofilm construct, yet progressive biofilm treatments continue to be overlooked in lieu of outdated or ineffective options. Evidence is mounting in favor of a dramatic assumptive shift to early and aggressive biofilm intervention implemented during wound bed preparation and performed throughout the wound healing continuum. These days, practice of EBM is hard to avoid, especially with every move scrutinized and examined under a performance microscope. Wound care providers are exasperated; even when they think they have applied EBM and considered every possible treatment, modality, and creative combination of advanced therapies in their toolbox at the suggested intervals (including serial debridement), they fail to achieve the same outcome from wound to wound. Laying blame for treatment failures on poor application of EBM may be a way to avoid one of the real issues behind the escalation in nonhealing wounds: a science-based approach to biofilm-directed wound care.
The lurking threat of biofilm impacts >90% of chronic wounds and 6% of acute wounds.6 With biofilm’s structure protecting as much as 99% of all wound bacteria, without biofilm-directed care, a wound is often life-long and life-ending.5,7 Admittedly, the majority of wounds we treat (such as diabetic ulcers) have etiologies that are fairly straightforward, but other wound etiologies often are varied and not well understood. A new level of biofilm understanding has connected root cause factors from wound to wound, acknowledging the pathogenic trail of inflammation linking a failure of wounds to heal to reactive biofilm responses.8 One Australian plastic surgeon has recognized that biofilms cause and stimulate scar tissue in as many as 60 000 breast surgery patients a year; biofilm gains access to the implant during surgery and forms a thin film over the implant, leading to inflammation and causing scar tissue and capsular contracture.9 From battlefield trauma wounds and burns to less studied but equally as devastating conditions such as recurring acne, hidradenitis suppurativa, recalcitrant scalp folliculitis, and the nefarious atrophie blanche (a background diagnosis for 9% to 38% of venous leg ulcers), there is a common inflammatory source, raising the question, Could part of the problem be biofilm and part of the healing solution be biofilm-directed care?7,8
Biofilm, with its partner inflammation, stalls healing and left unchecked often progresses to infection.7,10-12 Until recent research uncovered the Achilles’ heel of biofilm, it all but escaped treatment for several reasons: biofilm is not visually detectable, it forms quickly (often within minutes to hours of injury, much sooner than first believed), is hidden by inflammation in its initial stages and has been thought to involve free-floating bacteria, which are easily displaced by debridement or killed with topical treatments. These beliefs have fixated care options on free-floating bacteria, which addresses only a small part of the bacterial problem and causes treatment hesitation, thus allowing biofilm to proliferate and for pronounced infection symptoms to develop. Delayed attention or ineffective treatment nurtures biofilm, facilitating its spread even during bacterial eradication modalities and treatments that involve clinic-based debridement, dressings, antiseptics, and antibiotics.5-7,10-12 Convinced we have used all of the tools in our treatment toolbox, we watch and wait.
Fundamental wound care has not changed. Like the ABCs of cardiopulmonary resuscitation, we know what steps to follow, but we feel the need to jump from one treatment option to another when wounds fail to progress. Knowing that one of the top 3 reasons a wound fails to heal is infection, it may be time to reexamine our steps and reassess the evidence. Wound care science changes quickly; as such, it may be easy to confound the problem of nonhealing wounds by overlooking a source cause of not healing, sacrificing what new evidence is trying to tell us (ie, biofilm is everywhere). Awareness and acceptance of the need for infection prevention and definitive biofilm treatment has not kept pace with emerging evidence. As clinicians look for solutions, a slimy invisible biofilm may be sneakily contributing to the true nidus of many nonhealing wounds. If products and procedures such as outpatient debridement aren’t working, it’s time to reevaluate. Looking at wounds that refuse to heal through the lens that the failure to heal may be rooted in biofilm will provide a way to see nonhealing wounds in a new light. There are many reasons why wounds do not to heal; a biofilm-based infection should not be one of them.
Disclosure
Dr. Edens is Chief of Dermatology, Langley Dermatology Clinic, Hampton, VA. Ms. Stevenson is a clinical consultant, Next Science, Jacksonville, FL. The opinions and statements expressed herein are specific to the respective authors and not necessarily those of Wound Management & Prevention or HMP. This article was not subject to the Wound Management & Prevention peer-review process.
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。